2 completed, 1 withdrawn. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Small Cell Glioblastoma: new trials by email Literature Review of Small Cell Glioblastoma trials Research Report on Small Cell Glioblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma autologous dendritic cells pulsed with tumor lysate antigen Vaccine, Laboratory Biomarker Analysis, Nivolumab - Giant Cell Glioblastoma, Gliosarcoma | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2019-12-01 | 2020-07-24 | |
| A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH - Glioblastoma, Small Cell Glioblastoma | Phase 2 | Completed | Celldex Therapeutics | 127 | 2011-12-01 | 2020-02-17 |
| Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH - Glioblastoma, Small Cell Glioblastoma | Phase 3 | Completed | Celldex Therapeutics | 745 | 2011-11-01 | 2018-01-16 |
Glioblastoma (3) · Gliosarcoma (3) · Brain Neoplasms (2) · Neoplasms (2) · Oligodendroglioma (1) · Recurrence (1)
Astrocytoma (3) · Glioma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Neoplasms, Neuroepithelial (3) · Neuroectodermal Tumors (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Central Nervous System Neoplasms (2) · Neoplasms by Site (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Disease Attributes (1)
rindopepimut (2) · Bevacizumab (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Nivolumab (1) · Temozolomide (1) · sargramostim (1)
Celldex Therapeutics (2) · Jonsson Comprehensive Cancer Center (1)
United States (3) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Colombia (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · India (1) · Israel (1) · Italy (1)